Balveen Kaur博士

教育

Graduate School

Biotechnology; Banaras Hindu University, Varanasi, India

博士学位

佐治亚州亚特兰大的生物化学与分子生物学大学

Areas of Interest

Research Interests

Publications

Publication Information

同行评审的文章：

1. Kaur B，Avery AM和Doetsch PW。生物化学。37（33）：11599-11604，1998。
2. Avery AM, Kaur B, Taylor JS, Mello JA, Essigmann JM and Doetsch PW.: Substrate specificity of ultraviolet DNA Endonuclease (UVDE/Uve1p) from Schizosaccharomyces pombe. Nucleic Acids Research. 27(11): 2256-2264, 1999.
3.Kaur B,弗雷泽JL福瑞尔G S和Doetsc戴维h PW.: A Uve1p mediated mismatch repair pathway in Schizosaccharomyces pombe. Molecular and Cellular Biology. 19(7): 4703-4710, 1999.
4. Kaur B and Doetsch PW.: Ultraviolet Damage Endonuclease (Uve1p): a Structure and Strand-Specific DNA Endonuclease. Biochemistry. 39(19): 5788-5796, 2000.
5. Majbeesh NJ，Post DE，Willard MT，Kaur B，Van Meir Eg。：Geldanamycin通过前列腺癌细胞中的蛋白体途径诱导HIF-1α蛋白的降解。癌症研究。beplay苹果手机能用吗62（9）：2478-2482，2002。
6. Fulci G, Nobuaki I, Daniela M, Gernert KM, Hainaut P, Kaur B, Van Meir EG.: Initiation of human astrocytoma by clonal evolution of cells with progressive loss of functions in a patient with a 283H p53 germ line mutation. Cancer Research. 62(10): 2897-905, 2002. (Featured on Cover).
7. Brat DJ, Castellano-Sanchez A, Kaur B, Van Meir E.: Genetic and biologic progression in astrocytoma and their relation to angiogenic dysregulation. Adv. Anat. Pathol. 1(24-36), 2002.
8. Kaur B Brat DJ，Calkins CC，Van Meir E。：脑血管生成抑制剂1（BAI1）在正常脑和胶质母细胞瘤中差异表达，独立于p53表达。是。J. Pathol。162（1）：19-27，2003。
9. Brat DJ，Kaur B，Van Meir Eg。缺氧诱导基因表达和血管生成的遗传调节：与脑肿瘤有关。生物科学领域。8：D100-16，2003。
10. Brat DJ, Hunter SB, Pecot MP, Cohen C, Hammond EH, Devi NS, Kaur B, Van Meir EG.: Pseudopalisades in glioblastoma are hypoxic, express extracellular matrix proteases, and likely represent an actively migrating cell population. Cancer Research. 64(3): 920-927, 2004.
11. Kaur B，Tan C，Brat DJ，Van Meir Eg。：胶质瘤中血管生成的遗传和低氧调节。J神经肿瘤学。70（2）：229-43，2004。
12. Post DE, Devi NS, Li Z, Brat DJ, Kaur B, Nicholson A, Olson JJ, Zhang Z, Van Meir EG.: Cancer Therapy with a replicating adenovirus targeting the hypoxic microenvironment of tumors. Clinical Cancer Research. 10(24): 8603-12, 2004
13. *Kaur B. Khwaja FK, Severson EA, Matheny S, Brat DJ, Van Meir EG.: Hypoxia and the HIF pathway in glioma growth and angiogenesis. Neuro-Oncology. 7(2):134-153, 2005
14. Kaur B, Brat DJ, Devi NS, Van Meir EG. Vasculostatin, a natural BAI1 proteolytic fragment is an anti-angiogenic and anti-tumorigenic factor. (2005) Oncogene 24:3632-3642.
15. Fulci G，Breymann L，Gianni D，Kurozumi K，Rhee SS，Yu J，Kaur B，Louis DN，Weissleder R，Caligiuri MA，Chiocca EA：环磷酰胺通过抑制先天免疫反应来增强胶质瘤病毒疗法。美国国家科学院论文集。103（34）：12873-12878，2006。
16. Cutter，JL，Kurozumi，K，Chiocca EA，Kaur，B。：Gene Therapeutics：脑肿瘤疗法的未来？抗癌治疗的专家评论6（7）：1053-64，2006。
17. Lamfers ML, Fulci G, Gianni D, Tang Y, Kurozumi K, Kaur B, Moeniralm S, Saeki Y, Carette JE, Weisledder R, Vandertop WP, Beusechem VW, Dirven CMF, Chiocca EA.: Cyclophosphamide increases transgene expression mediated通过通过生物发光成像监测的神经胶质瘤中的溶瘤腺病毒。分子疗法。14：779-788，2006。
18. Fulci G，Dmitrieva N，Gianni D，Fontana EJ，Pan X，Kaur B，Lawler SE，Lee RJ，Marsh CB，Brat DJ，Brat DJ，Rooijen NV，Rachamimov，Rachamimov AS，Weissleder R，Martuza RL，Chiocca Ea。::巨噬细胞或小胶质细胞增加了注射的溶瘤病毒的滴度。癌症研究。beplay苹果手机能用吗67（19）：9398-406，2007。
19. Hardcastle J, Kurozumi K, Chiocca EA, Kaur B.: Oncolytic Viruses driven by tumor specific promoters. Current Cancer Drug Targets. 7(2): 181-189, 2007.
20. *Kurozumi K，Hardcastle J，Thakur R，Yang M，Christoforidis G，Fulci G，Hochberg FH，Weissleder RW，Carson W，Chiocca EA，Kaur B。：调节肿瘤微环境以增强溶液性病毒治疗。国家癌症研究所杂志。99（23）：1768-81，2007。 *伴随JNCI的社论。
21. Kurozumi K, Hardcastle J, Thakur R, Shroll J, Chiocca EA, Kaur B.: Oncolytic HSV-1 infection of tumors induces angiogenesis and upregulates cyr61. Molecular Therapy. 16(8):1382-91, 2008.
22. Haseley A，Alvarez-Breckenridge C Chaudhury AR，Kaur B。：胶质瘤的溶瘤病毒疗法的进步。CNS药物发现的最新专利。4（1）：1-13，2009。
23. Kaur B, Cork SM, Sandberg E, Devi NS, Zhang Z, Klenotic PA, Febbraio M, Shim H, Mao H, Tucker-Burden C, Silverstein RL, Brat DJ, Olson JJ, and Van Meir EG.: Vasculostatin inhibits intracranial glioma growth and negatively regulates in vivo angiogenesis through a CD36-dependent mechanism. Cancer Research. 69(3):1212-20, 2009.
24. Barth RF, Kaur B.: Rat brain tumor models in experimental neuro-oncology: the C6, 9L, T9, RG2, F98, BT4C, RT-2 and CNS-1 gliomas. Journal of Neuro-oncology. 94(3):299-312, 2009.
25. Alvarez-Breckenridge C, Kaur B and Chiocca EA.: Pharmacologic and chemical adjuvants in tumor virotherapy. Chemical reviews 109(7): 3125-3140, 2009.
26. Kaur B, Cripe T, Chiocca EA.: “Buy one get one free:” armed viruses for the treatment of cancer cells and their microenvironment. Current Gene Therapy. 9(5):341-355, 2009.
27. Hardcastle J, Kurozumi K, Dmitrieva N, Sayers MP, Ahmad S, Waterman P, Weissleder R, Chiocca EA, Kaur B.: Enhanced antitumor efficacy of vasculostatin (Vstat120) expressing oncolytic HSV-1. Molecular Therapy 18(2): 285-294, 2010.
28. Klenotic PA，Huang P，Palomo J，Kaur B，Van Meir EG，Vogelbaum MA，Febbraio M，Gladson CL，Silverstein RL。：富含组氨酸的糖糖蛋白调节Vasculostatin的抗血管生成作用。美国病理学杂志176（4）：2039-50，2010。
29. Nakashima H, Kaur B, Chiocca EA.: Directing systemic oncolytic viral delivery to tumors via carrier cells. Cytokine & Growth Factor Reviews. 21(2-3):119-126, 2010.
30. Wojton J, Kaur B.: Impact of tumor microenvironment on oncolytic viral therapy.: Cytokine & Growth Factor Reviews. 21(2-3):127-134, 2010.
31. *Dmitrieva N，Yu L，Viapiano M，Chiocca EA，Cripe T，Glorioso J，Kaur B。：Choindroitinase ABC I增强了肿瘤病毒的肿瘤内分布和抗肿瘤功效。临床癌症研究。beplay苹果手机能用吗17（6）：1362-1372，2011。 *伴随分子治疗的研究重点。beplay苹果手机能用吗PMC3140790
32. Williams SP, Nowicki MO, Liu F, Press R, Godlewski J, Abdel-Rasoul M, Kaur B, Fernandez SA, Chiocca EA Lawler SE.: Indirubins decrease glioma growth and invasion by blocking migratory phenotypes in both the tumor and stromal endothelial cell compartments. Cancer Research. 71(16):5374-80, 2011.
33. Chiocca EA, Aguilar LK, Bell S, Kaur B, Hardcastle J, Cavaliere R, McGregor J, Lo S, RayChaudhuri A, Chakarvarti AG, Herbert JN, Harris KS, Grossman RG, Trask TW, Baskin DS, Monterroso CM,Manzanera AG，Aguilar-Cordova E，New PZ。：基因介导的细胞毒性免疫疗法的IB期研究，用于预先手术和针对恶性神经胶质瘤的强化时机辐射。临床肿瘤学杂志29（27）：3611-9，2011年。
34. Yoo JY，Haseley A，Bratasz A，Chiocca EA，Zhang JY，Cain JY，Cain D，Powell K，Kaur，B。：34.5岁的抗肿瘤功效：转录的重新定位和VSTAT120表达阳性病毒。分子疗法。20（2）：287-97，2012。
35. Cork SM, Kaur B, Devi NS, Cooper L, Saltz JH,4, Sandberg EM, Kaluz S, Van Meir EG.: A furin/MMP-14 proteolytic cascade releases a novel 40 kDa Vasculostatin from tumor suppressor BAI1. Oncogene 13;31(50):5144-52, 2012.
36. Kaur B, Chiocca EA, Cripe TP.: Oncolytic HSV-1 virotherapy; Clinical experience and opportunities for progress. Current Pharmaceutical Biotechnology, Special Issue “Virotherapy”. 1:13(9):1842-51, 2012.
37. Alvarez-Breckenridge C, Yu J, Price R, Wei M, Wang Y, Nowicki P, Yoonhee M, Bergin S, Hwang C, Soledadad F, Kaur B, Caligiuri M, Chiocca EA.: The HDAC inhibitor valproic acid lessens NK cell action against oncolytic virus-infected glioblastoma cells with inhibition of STAT5/T-BET signaling and IFNgamma generation. Journal of Virology 86(8):4566-77, 2012.
38. *Haseley A, Boone S, Wojton J, Yu L, Yoo JY, Yu J, Kurozumi K, Glorioso J, Caligiuri M, Kaur B.: Extracellular matrix protein CCN1 limits oncolytic efficacy in glioma. Cancer Research, 72(6):1353-62, 2012. *Accompanied by research highlights in Molecular therapy.
39. Alvarez-Breckenridge C，Yu J，Kaur B，Caligiuri M，Chiocca EA。：解密溶瘤病毒与天然杀伤细胞之间的多方面关系。病毒学的进步。doi：10.1155/2012/702839，2012。
40. Suh S, Yoo JY, Nuovo GJ, Jeon YJ, Kim S, Lee TJ, Kim T, Bakacs A, Alder H, Kaur B, Aqeilan RI, Pichiorri F, Croce CM.: miR-25/32 restore p53 activity. MicroRNAs/TP53 feedback circuitry in glioblastoma multiforme. Proceedings of the National Academy of Sciences USA. 09(14):5316-21, 2012.
41. Wurdinger T, Gatson NN, Balaj L, Kaur B, Breakefield X, Pegtel DM.: Extracellular Vesicles and the Convergence with Viral Pathways. Advances in Virology, doi: 10.1155/2012/767694, 2012.
42.Yoo司法院,Pradarelli J, Haseley谷湖Wojton Ja A, Bratasz A, Alvarez-Breckenridge C, Powell K, Pan Q, Mazar A, Teknos T, Old M, Chiocca EA, Glorioso J, Kaur B.: Copper chelation antitumor efficacy of oncolytic virus by increasing its serum stability and inhibiting angiogenesis. Clinical Cancer Research, 18(18):4931-41, 2012
43. Gatson N, Chiocca EA, Kaur B.: Anti-angiogenic Gene Therapy in the Treatment of Malignant Gliomas. Neuroscience Letters. 527(2):62-70, 2012.
44. Onishi M，Ichikawa T，Kurozumi K，Fujii K，Yoshida K，Inoue S，Michiue H，Chiocca EA，Kaur B，日期I。神经病理学。33（2）：162-74，2013。
45. Alvarez-Breckenridge CA, Yu J, Price R, Wojton J, Pradarelli J, Mao H, Wei M, Wang Y, Hardcastle J, Fernandez SA, Kaur B, Lawler SE, Vivier E, Mandelboim O, Moretta A, CaligiuriM，Chiocca EA。：NK细胞通过NKP30和NKP46天然细胞毒性受体阻碍了胶质母细胞瘤的病毒疗法。自然医学。18（12）：1827-34，2012。
46. Uchida H, Marsulli M Yoo JY, Haseley A, Mazzacurati L, , Nakano K, Goins WF, Hong CS, Chan J, Baek H, Kwon H, Kumagai I, Kuroki M, Kaur B, Chiocca EA, Grandi P, Cohen JB, and Glorioso JC.: Effective Treatment of Glioblastoma Using EGFR-Retargeted oHSV. Molecular Therapy. 21(3):561-9, 2013
47. Currier M, Eshun FK, Sholl A, Chernoguz, Crawford K, Divanovic S, Boon L, Goins WF, Frischer JS, Collins MH, Leddon JF, Baird WH, Haseley A, Streby KA, Wang P, Hendrickson BW, Brekken RA, Kaur B, Hildeman D, Cripe TP.: VEGF Blockade Enables Oncolytic Cancer Virotherapy in Part by Modulating Intratumoral Myeloid Cells. Molecular Therapy (5):1014-23, 2013.
48. Price RL，Song J，Bingmer K，Kim TH，Yi JY博士，Nowicki MO，MO X，Hollon T，Hollon T，Murnan E，Alvarez-Breckenridge C，Fernandez S，Kaur B，Rivera B，Rivera A，Rivera A，Oglesbee M，Oglesbee M，Cook C C，夸恩在肿瘤抑制突变的背景下，巨细胞病毒有助于胶质母细胞瘤。癌症研究，73beplay苹果手机能用吗（11）：3441-50，2013。
49. Wojton J, Chu Z, Mathsyaraja H, Meisen W, Denton N, Kwon CH, Chow LM, Palascak M, Franco R, Bourdeau T, Thornton S, Ostrowski M, Kaur B, and Qi X.: “Systemic delivery of SapC-DOPS has anti-angiogenic and antitumor effects against glioblastoma” Molecular Therapy. 21(8):1517-25, 2013.
50. Onishi M，Kurozumi K，Ichikawa T，Michiue H，Fujii K，Ishida J，Shimazu Y，Chiocca EA，Kaur B，日期I。Springer Plus 15; 2（1）：160，2013。
51. Stephenson JR, Paavola KJ, Schaefer SA, Kaur B, Van Meir EG, Hall RA.: Brain Specific angiogenesis Inhibitor-1 (BAI1) signaling Regulation and enrichment in the postsynaptic density. Journal of Biological Chemistry. 288(31):22248-56, 2013.
52. racoma io，Meisen WH，Kaur B，Snapka RM，Wani AW。：胸腺醌抑制自噬并诱导胶质母细胞瘤细胞中caspase介导的，caspase无关的细胞死亡。PLOS一个。8（9）：E72882，2013
53. Fujii K, Kurozumi K, Ichikawa T, Onishi M, Shimazu Y, Ishida J, Chiocca EA, Kaur B, Date I.: The integrin inhibitor cilengitide enhances the anti-glioma efficacy of Vasculostatin expressing oncolytic virus. (2013) Cancer Gene Therapy 20(8):437-44. NIHMSID: 511971.
54. Chu Z, LaSance K, Blanco V, Kwon CH, Kaur B, Frederick M, Thornton S, Lemen L, Qi X.: In Vivo Optical Imaging of Brain Tumors and Arthritis Using Fluorescent SapC-DOPS Nanovesicles. Journal of Visualized Experiments. doi: 10.3791/51187, 2013.
55. Okemoto K，Wagner B，Meisen H，Haseley A，Kaur B，Chiocca EA。STAT3激活促进了神经胶质瘤细胞中的溶瘤HSV1复制。PLOS一个。8（8）：E71932。doi：10.137，2013。
56. Okemoto K, Kasai K, Wagner B, Haseley A, Meisen H, Bolyard C, Kaur B, Chiocca EA.: DNA demethylating agents synergize with oncolytic HSV1 against malignant gliomas Clinical Cancer Research. 19(21):5952-9, 2013.
57. Yan F，Alinari L，Lustberg M，Martin K，Cordero-Nieves，H，Banasavadi-Siddegowda，Y，Y，Virk，S，Barnholtz-Sloan J，Hlavin Bell E，Wojton J，Wojton J，Jacob N，Jacob N，Chakravarti A，Chakravarti A，Chakravarti A，Chakravarti A，Chakravarti o，Wu X，Lapalombella R，Datta J，Yu B，Gordon K，Haseley A，Patton JT，Smith P，Ryu J，Zhang X，Mo X，Mo X，Marcucci G，Nuovo G，Kwon C，Kwon C，Kwon C，Byrd J，Chiocca EA，Chiocca EA，Li LiC，Sif A，Samson J，Lawler SE，Kaur B*，Baiocchi Ra*：蛋白精氨酸甲基转移酶PRMT5作为胶质母细胞瘤中候选治疗靶的遗传验证。癌症研究15;beplay苹果手机能用吗 74（6）：1752-65，2013。
58. Yoo JY, Hurwitz B, Bolyard C, Yu J, Zhang J, Selvendiran K, Rath KS, He S, Bailey Z, Eaves D, Cripe T, Parris DS, Caligiuri MA, Old M, Kaur B.: Bortezomib-induced unfolded protein response increases oncolytic HSV-1 replication resulting in synergistic necroptic cell death. Clinical Cancer Research. 20(14):3787-98, 2014.
59. Kim TH, Song J, Kim SH, Parikh AK, Mo X, Palanichamy K, Kaur B, Yu J, Yoon SO, Nakano I, Kwon CH.: Piperlongumine treatment inactivates peroxiredoxin 4, exacerbates endoplasmic reticulum stress, and preferentially kills high-grade glioma cells. Neuro-Oncology. 16(10):1354-64, 2014.
60. Thorne AH，Meisen H，Russell L，Yoo JY，Bolyard CM，Lathia JD，Rich J，Rich J，Rich J，Puduvalli V，Yu J，Caligiuri M，Tridandapani S，Kaur B.：CCN1在巨噬细胞中的作用。分子疗法。22（9）：1678-87，2014。
61. Kim Y, Lee HG, Dmitrieva N, Kim J, Kaur B, Friedman A.: Choindroitinase ABC I-mediated enhancement of oncolytic virus spread and anti-tumor efficacy: A mathematical model. Plos One e102499. doi: 10.1371/journal.pone.0102499. eCollection, 2014.
62. Wojton J, Meisen HM, Jacob N, Thorne A, Hardcastle J, Denton N, Chu Z, Dmitrieva N, Marbarthsh R, Van Meir EG, Kwon CH, Chakravarti A, Qi X, Kaur B.: SapC-DOPS-诱导的溶酶体细胞死亡与胶质母细胞瘤中的TMZ协同作用。Oncotarget。5（20）：9703-9，2014。
63. Van Brocklyn JR, Wojton J, Meisen WH, Kellough DA, Ecsedy JA, Kaur B, Lehman NL.: Aurora-A inhibition offers a novel therapy effective against intracranial glioblastoma. Cancer Research 74(19):5364-70, 2014.
64. Suh S，Yoo JY，Cui R，Kaur B，Huebner K，Lee TK，Aqeilan R，Croce c。：Fhit基因通过调节MicroRNAS在肺癌中抑制转移和上皮 - 间质转变（EMT）。PLOS遗传学。10（10）：E1004652，2014。
65. Bolyard CM, Yoo JY, Wang PY, Sainin U, Rath KS, Cripe TP, Zhang J, Selvendiran K, Kaur B.: Doxorubicin synergizes with 34.5ENVE to enhance antitumor efficacy against metastatic ovarian cancer. Clinical Cancer Research 20(24):6479-94, 2014.
66. Meisen HW, Dubin S, Sizemore ST, Mathsyaraja H, Thies K, Lehman NL, Boyer P, Jaimie-Ramirez AC, Elder JB, Powell K, Chakravarti A, Ostrowski M, Kaur B.: Changes in BAI1 and Nestin expression are prognostic indicators for survival and metastases in breast cancer and provide opportunities for dual targeted therapies. Molecular Cancer Therapeutics 14(1):307-14, 2015.
67. Mazzacurati L, Marzilli M, Reinhart B, Miyagawa Y, Uchida H, Goins WF, Li A, Kaur B, Caligiuri M, Cripe T, Chiocca N, Amankulor N, Cohen JB, Glorioso JC, Grandi P.: Use of miRNA Response Sequences to Block Off-target Replication and Increase the Safety of an Unattenuated, Glioblastoma-targeted Oncolytic HSV. Molecular Therapy. 23(1):99-107, 2015.
68. Ammirati M1，Lamki T，Chitnis G，Yang X，Russell D，Coble D，Kaur B，Knopp M，Knopp M，Moore S，Ziaie B。：在体内脑电泳中 - 一种用于CNS疾病化学疗法的新方法。专家意见。药物输送。2015年2月10日：1-8，2015。
69. Lee TJ，Haque F，Shu D，Yoo JY，Li H，Yokel RA，Horbinski C，Kim TH，Kim SH，Kim SH，Kwon CH，Nakano I，Nakano I，Kaur B，Guo P，Croce CM。：RNA纳米粒子作为矢量针对靶向siRNA递送到胶质母细胞瘤小鼠模型中。Oncotarget。20; 6（17）：14766-76，2015。
70. Jacobsen K, Russell L, Kaur B, Friedman A.: Effects of CCN1 and Macrophage Content on Glioma Virotherapy: A Mathematical Model. Bulletin of mathematical Biology. 77(6): 984-1012, 2015.
71. Yoo JY, Yu JG, Kaka A, Pan Q, Kumar P, Kumar B, Zhang J, Mazar A, Teknos T, Kaur B, Old M.: ATN-224 enhances antitumor efficacy of oncolytic herpes virus against both local and metastatic head and neck squamous cell carcinoma. Molecular Therapy Oncolytics doi:10.1038/mto.2015.8, 2015.
72. Meisen HW，Wohleb ES，Jaime-Ramirez CA，Bolyard CM，Yoo JY，Russell L，Hardcastle J，Dubin S，Muili K，Yu J，Yu J，Caligiuri MA，Godbout J，Kaur B。分泌的TNFα在胶质母细胞瘤肿瘤微环境中的溶瘤HSV-1治疗上分泌。临床癌症研究15;beplay苹果手机能用吗21（14）：3274-85，2015。伴随着神经外科的评论（2015年8月； 77（2）：N18-20）
73. Han J, Chu J, Keung Chan W, Zhang J, Wang Y, Cohen JB, Victor A, Meisen WH, Kim SH, Grandi P, Wang QE, He X, Nakano I, Chiocca EA, Glorioso JC, Kaur B, Caligiuri MA, Yu J.: CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells. Sci Rep. Jul 9; 5:11483. doi: 10.1038/srep11483, 2015.
74. CanellaA, Cordero H, Sborov DW, Cascione L, Smith E, Radomska HS, Stiff A, Consiglio J, Caserta E, Rizzotto L, Zanesi N, Stefano V, Kaur B, Mo X, Byrd JC, Hofmeister CC and Pichiorri F.: HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide. Oncotarget. 6(31):31134-50. doi: 10.18632/oncotarget.5290, 2015.
75. Cheng C，Ru P，Geng F，Liu J，Wu X，Cheng X，Euthine V，Hu P，Guo JY，Lefai E，Kaur B，Nohturfft A，Ma J，Ma J，Chakravarti A，Guo D。SCAP的介导的N-糖基化对于SREBP-1激活和肿瘤生长至关重要。癌细胞。28（5）：569-81，2015。
76. Han J, Chen X, Chu J, Xu B, Meisen WH, Chen L, Zhang L, Zhang J, He X, Wang QE, Chiocca EA, Kaur B, Caligiuri MA, Yu J.: TGF-β treatment enhances glioblastoma virotherapy by inhibiting the innate immune response. Cancer Research. 75(24):5273-82, 2015.
77. Welker AM，Jaros BD，Puduvalli VK，Imitola J，Kaur B，Beattie CE。：斑马鱼中的标准化原位异种移植物揭示了胶质瘤细胞系的特异性特异性特异性和肿瘤细胞异质性。Dis Model Mech。12月10日PII：DMM.022921，2015年。
78. Stiff A，Caserta E，Sborov DW，Nuovo GJ，Mo X，Schlotter YS，Canella A，Smith E，BADWAY J，Old M，Jaime-Ramirez AC，Yan P，Benson P，Benson DM，Byrd J，Byrd J，Byrd J，Baiocchi R，Kaur R，Kaur，Kaur，Kaur，KaurB，Hofmeister CC和Pichiorri F。：组蛋白脱乙酰基酶抑制剂增强了多发性骨髓瘤中嗜酸病毒的治疗潜力。分子癌疗法。15（5）：830-41。doi：10.1158/1535-7163.MCT-15-0240-T，2016年。
79. Wojton J, Meisen WH, Kaur B.: How to Train Your Glioma Cells to Die: Molecular Challenges in Cell Death. Journal of Neuro-Oncology. 126(3):377-84, 2016. * Figure selected for cover.
80. Old M, Wise-Draper T, Wright CL, Kaur B, Teknos T.: The current status of oncolytic viral therapy for head and neck cancer. World Journal of Otolaryngology-Head and Neck Surgery. 2(2):84-89, 2016.
81. Barth RF, Wu G, Meisen WH, Nakkula RJ, Yang W, Huo T, Kellough DA, Kaumaya P, Turro C, Agius L, Kaur B.: Design synthesis and evaluation of cisplatin containing EGFR targeting bioconjugates as potential therapeutic agents for brain tumors. Oncotargets and Therapy 2016 9:2769-81. doi: 10.2147/OTT.S99242, 2016.
82. Chen X, Han J, Chu J, Zhang L, Zhang J, Chen C, Chen L, Wang Y, Wang H, Yi L, Elder BJ, Wang Q-E, He X, Kaur B, Chiocca EA, Yu J.: A combinational therapy of EGFR-CAR NK cells and oncolytic herpes simplex virus 1 for breast cancer brain metastases. Oncotarget. 7(19):27764-77. doi: 10.18632/oncotarget.8526, 2016.
83. Quispe CNE，Vicetti Miquel RD，Boyaka PN，Hall-Stoodley L，Kaur B，Kaur B，Trout W，Trout W，Pavelko SD，Cherpes Tl。：Medroxyprogesterone乙酸盐和黎脱沃甲酸酯和黎脱沃莫氏菌的渗透性增加了生殖器粘膜的渗透性，并增强了对生殖器Herspes Simplex Simplex Simplex Virection typection的易感性。粘膜免疫学。9（6）：1571-1583。doi：10.1038/mi.2016.22，2016。
84. Bhallamudi YP, Xue R, Purser CM, PresleyKF, Banasavadi-Siddegowda YK, Hwang, J, Kaur B, Hammel C, Poirier MG, Lannutti JJ, Pandian RP.: .DNanofiber based paramagnetic probes for rapid real time oximetry. Biomedical Microdevices. 18(2):38. doi: 10.1007/s10544-016-0063-1, 2016.
85. Geng F，Cheng X，Wu X，Yoo JY，Cheng C，Guo Jy，Mo X，Ru P，Hurwitz B，Kim S，Otero J，Puduvalli VK，Lefai E，Ma J，Ma J，Nakano I，Nakano I，Horbinski C，Horbinski C，Horbinski C，Kaur B，Chakravarti A，Guo D。：SOAT1的抑制可通过阻断SREBP-1介导的脂质形成来抑制胶质母细胞瘤的生长。临床癌症研究。beplay苹果手机能用吗22（21）：5337-5348，2016
86. Yoo JY，Jaime-Ramirez AC，Bolyard C，Dai H，Nallanagulagari T，Wojton J，Hurwitz B，Hurwitz B，关系T，Yu JG，Lee TJ，Lotze MT，Lotze MT，Zhang J，Croce C，Croce C，Yu J，Yu J，Caligiuri J，Caligiuri Ma，Old Old Old Old Old Old Old Old Old Old Old Old Old OldM，Kaur B。：硼替佐米处理使溶瘤HSV-1治疗肿瘤对NK细胞免疫疗法。临床癌症研究。beplay苹果手机能用吗22（21）：5265-5276，2016。伴随着临床癌症研究的评论（2016年11月1日； 22（21）：5164-5166）beplay苹果手机能用吗
87. Banasavadi-Siddegowda YK, Russell L, Zhang J, Karkhanis VA, Imitola J, Baiocchi R, Kaur B.: PRMT5-PTEN molecular pathway regulates senescence and self-renewal of Glioblastoma stem-like cells. Oncogene 36, 263–274, 2017.
88. Kesanakurti D, Maddirela D, Banasavadi-Siddegowda YK, Lai TH, Qamri Z, Jacob NK, Sampath D, Mohanam S, Kaur B, Puduvalli VK.: A Novel Interaction of PAK4 with PPARγ to Regulate Nox1 and Radiation-Induced Epithelial-to-Mesenchymal Transition in Glioma. Oncogene. doi: 10.1038/onc.2016.261. [Epub ahead of print], 2017
89.李TJ, Yoo司法院,李蜀D, H,张J, Yu J,农协ime-Ramirez A, Acunzo M, Romano G, Cui R, Sun HL, Luo Z, Old M, Kaur B, Guo P, Croce CM.: RNA nanoparticle based targeted therapy for glioblastoma through inhibition of oncogenic miR-21. Molecular Therapy. pii: S1525-0016(16)45424-9. doi: 10.1016/j.ymthe.2016.11.016. [Epub ahead of print], 2017
90. Alena Jaime-Ramirez C, Dmitrieva N, Yoo JY, Banasavadi-Siddegowda Y, Zhang J, Relation T, Bolyard-Blessing C, Wojton J, Kaur B.: Humanized Chondroitinase ABC Sensitizes Glioblastoma Cells to Temozolomide. Journal of Gene medicine. Mar;19(3). doi: 10.1002/jgm.2942, 2017.
91. Jaime-Ramirez AC, Yu JG, Caserta E, Yoo JY, Zhang J, Lee TJ, Hofmeister C, Lee JH, Kumar B, Pan Q, Kumar P, Baiocchi R, Teknos T, Pichiorri F, Kaur B, Old M.: Reolysin and Histone Deacetylase Inhibition in the Treatment of Head and Neck Squamous Cell Carcinoma Molecular Therapy Oncolytics. published online May 19, 2017.
92. Bolyard C, Meisen WH, Banasavadi-Siddegowda Y, Hardcastle J, Yoo JY, Wohleb ES, Wojton J, Yu J, Dubin S, Khosla M, Xu B, Smith J, Alvarez-Breckenridge C, Pow-anpongkul P, Pichiorri F, Zhang J, Old M, Zhu D, Van Meir EG, Godbout J, Caligiuri MA, Yu J, Kaur B.: BAI1 Orchestrates Macrophage Inflammatory Response to HSV Infection- implications for Oncolytic Viral Therapy. Clinical Cancer Research. 23(7):1809-1819, 2017.
93. Saini U, Naidu S, Elnaggar AC, Bid HK, Wallbillich JJ, Bixel K, Bolyard C, Suarez AA, Kaur B, Kuppusamy P, Hays J, Goodfellow PJ, Cohn DE, Selvendiran K.: Elevated STAT3 expression in ovarian cancer ascites promotes invasion and metastases: a potential therapeutic target. Oncogene. 12;36(2):168-181, 2017.
94. Ru P, Hu P, Geng F, Mo X, Cheng C, Yoo JY, Cheng X, Wu X, Guo JY, Nakano I, Lefai E, Kaur B, Chakravarti A, Guo D*.: Feedback Loop Regulation of SCAP/SREBP-1 by miR-29 Modulates EGFR Signaling-driven Glioblastoma Growth. Cell Reports 16(6):1527-35. doi: 10.1016/j.celrep.2016.07.017, 2017.
95. Jaime-Ramirez AC，Yu JG，Caserta E，Yoo JY，Zhang J，Lee TJ，Hofmeister C，Lee JH，Kumar B，Pan Q，Kumar P，Baiocchi R，Teknos T，Teknos T，Teknos T，Pichiorri F，Pichiorri F，Pichiorri F，Kaur B，Old Old Old Old Old Old Old，Old Old，Old Old，M. reolysin和组蛋白脱乙酰基酶在治疗头颈鳞状细胞癌中。（2017）分子疗法癌术。doi：http：//dx.doi.org/10.1016/j.omto.2017.05.002。
96. Canella A, Welker AM, Yoo JY, Xu J, Abbas FS, Kesanakurti D, Nagarajan P, Beattie CE, Sulman EP, Liu JL, Gumin J, Lang FF, Gurcan M, Kaur B, Sampath D, Puduvalli VK. Efficacy of Onalespib a Long-acting Second Generation HSP90 Inhibitor as a Single Agent and in Combination with Temozolomide against Malignant Gliomas. (2017) Clinical Cancer research. clincanres.3151.2016. doi: 10.1158/1078-0432.CCR-16-3151. [Epub ahead of print]
97. Dai HS, Griffin N, Bolyard C, Mao HC, Zhang J, Cripe TP, Suenaga T, Arase H, Nakano I, Chiocca EA, Kaur B, Yu J, Caligiuri MA. The Fc Domain of Immunoglobulin Is Sufficient to Bridge NK Cells with Virally Infected Cells. (2017) Immunity. 18;47(1):159-170.e10. doi: 10.1016/j.immuni.2017.06.019.
Invited Articles (Reviews, Editorials, etc.) in Journals
98. Kaur B，Chiocca EA。：极端疾病的极端治疗。未来的微生物学。1（4）：351-353，2006。
99. Kaur B, Chiocca EA. Personalizing Oncolytic Virotherapy. (2007) Molecular Therapy. 15(1):6-7.
100. Meisen H, Kaur B. How can we trick the immune system to overcome the detrimental effects of oncolytic viral therapy to treat glioblastoma? (2013) Expert Review of Neurotherapeutics. 13(4):341-343. doi: 10.1 Development of Therapeutic agents Handbook586/ern.13.25.
101. Wojton J，Elder B，KaurB。自噬抑制剂作为胶质母细胞瘤的治疗效率如何？3（1）5-7。（2014）CNS肿瘤学。
102. Russell L, Bolyard C, Banasavadi-Siddegowda Y, Weiss A, Zhang J, Shakya R, Powell K, Kaur B. Sex as a biological variable in response to temozolomide. (2017) Neuro-Oncology

书籍章节：

103. Barth R, Kaur B.: Immunocompetent intracranial Rat glioma models for preclinical therapeutic evaluations of novel therapies. In CNS Cancer. ISBN: 978-1-60327-552-1, 2009. Editor: Erwin Van-meir. Publisher: Springer.
104. Lee TJ，Haque F，Vieweger M，Yoo JY，Kaur B，Guo P，Croce CM。分子生物学的方法。RNA纳米技术和治疗学。doi：10.1007/978-1-4939-2562-9_10。，2015年。©Springer Science+商业媒体纽约2015
105.Kaur B, Lesinsky G,乔杜里。:从基本概念t to the Clinics: Development of Novel Large Molecule Cancer Therapeutics. Pharmaceutical Sciences Encyclopedia. DOI: 10.1002/9780470571224.pse402. 4:1-39, 2010. Editors; Shayne C. Gad. Publisher: John Wiley & Sons. DOI: 10.1002/9780470571224.pse402
106. Price R, Kaur B, Chiocca EA.: Herpes Simplex Virus 1 for Cancer Therapy. In Gene-Based Therapies for Cancer. Current Cancer Research Book Series. DOI: 10.1007/978-1-4419-6102-0_12, 2010. Editor: Jack A Roth. Publisher: Springer, New York.